Resolution of Organ Injury in Acute Pancreatitis - RESORP (RESORP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03342716|
Recruitment Status : Active, not recruiting
First Posted : November 17, 2017
Last Update Posted : June 11, 2020
Acute pancreatitis (AP) is inflammation of the pancreas usually triggered by gallstones or drinking excessive alcohol. 80% of people who have an episode of AP will recover without complications. However, 20% will require treatment in high dependency or intensive care for multiple organ dysfunction (AP-MODS). It is known that this negatively affects recovery and can have a lasting effect on health although it is incompletely understood what causes this.
Aim: To recruit 500 patients with acute pancreatitis. Participants will be assessed at recruitment and and again at 3 and 36 months. Recovery of organ function will be serially measured and the presence of novel factors important in recovery assessed.
|Condition or disease|
Acute pancreatitis (AP) is a common and devastating disease with an annual incidence of 22-30 per 100,000 in the UK. The incidence is increasing. AP is most commonly triggered by gallstones or alcohol excess and has a range of outcomes, from complete resolution to death, with an overall mortality in Scotland of 5.2%. AP is characterised by acute inflammation of the pancreas, which initiates a cascade of inflammatory events throughout the body that can lead to multiple organ dysfunction syndrome (MODS) in approximately 25% of AP patients. Mortality in AP is greatest in those patients who develop MODS, with death rates reported to be up to 28%.
The development of persistent organ failure characterises severe AP (SAP) as defined in the revised Atlanta classification, and is strongly predictive of a fatal outcome. A significant proportion of research has focussed on reducing mortality and morbidity in the first week. As a consequence, it remains to be seen whether the patterns of early organ dysfunction are reflected in the causes of long-term mortality and morbidity.
Recently published data from a retrospective analysis of patients admitted to the Royal Infirmary of Edinburgh with acute pancreatitis has shown that the early development of MODS is associated with an increased mortality rate up to 10 years after the index presentation. This strongly suggests that MODS in acute pancreatitis (AP-MODS) has a persistent and deleterious impact on patients' physiological status, though the exact nature of this pathology remains to be characterised. Recent data has indicated that the severity of the first attack of AP significantly influences the risk of progression to chronic pancreatitis, and therefore subsequent long-term morbidity.
This observational clinical cohort study aims to characterise the nature and extent of the pathophysiological impact of SAP on organ function over the first 3 years following the index event and the long-term deleterious effect of SAP. This will be achieved by prospectively evaluating the pathophysiological consequences of an episode of AP by measuring organ system function in patients recruited during a hospital admission with AP. We will obtain an in-depth assessment of patients' health at presentation, and at 3 months and 36 months after the first episode of AP using markers of organ function and/or disease in the peripheral blood. In a nested cohort within the main study cohort, we will conduct cardiorespiratory evaluation tests (including exercise testing), specialised blood tests of the immune system, tests for precision medicine, and imaging to assess structure and function of key organ systems.
The results of this study will inform the design of future interventions designed to improve the long-term prognosis of patients.
|Study Type :||Observational|
|Actual Enrollment :||229 participants|
|Official Title:||Resolution of Organ Injury in Acute Pancreatitis - RESORP|
|Actual Study Start Date :||November 27, 2017|
|Estimated Primary Completion Date :||May 2023|
|Estimated Study Completion Date :||May 2023|
Patients with a clinical or radiological diagnosis of acute pancreatitis (AP)
Subgroup of patients with a clinical or radiological diagnosis of acute pancreatitis (AP) who will undergo additional assessments and scans
- Annual incidence of new-onset type 3c diabetes mellitis in patients with AP [ Time Frame: 66 months ]Do patients that have had AP develop type 3c diabetes mellitis more frequently?
- Nested cohort only - difference in the 3 month to 36 month change in pancreatic fibrosis index between participants with AP with MODS and those with AP without MODS [ Time Frame: 66 months ]Assess any damage to pancreas at 3 and 36 months and monitor how this changes throughout the course of the trial comparing participants with AP only and those with AP and MODS
- Specific gene and promoter sequence variation between participants with AP and AP-MODS [ Time Frame: 66 months ]Define any gene and promoter sequence variation between participants with AP and AP-MODS; machine learning approach
- miRNA signatures of disease severity and resolution [ Time Frame: 66 months ]Comparing patterns of gene expression in mild/moderate/severe cases of AP; machine learning approach
- Metabolomic profiling of AP resolution. [ Time Frame: 66 months ]Comparing patterns of metabolite expression in mild/moderate/severe cases of AP; machine learning approach
- Incidence of premature cellular senescence as a pathological consequence of AP-MODS. [ Time Frame: 66 months ]Investigating pathological consequences of AP-MODS compared to AP without MODS
- Alteration in immune cell subset phenotype as a long-term response to AP-MODS [ Time Frame: 66 months ]Investigating changes to the phenotype of immune cell subsets following an episode of AP; descriptive statistics
- Cardiorespiratory dysfunction as a legacy of endothelial injury during AP-MODS [ Time Frame: 66 months ]Determination of cardiorespiratory function following AP using physiological measures including cardiopulmonary exercise testing to determine anaerobic threshold. Descriptive measures.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03342716
|Royal Infirmary of Edinburgh|
|Edinburgh, United Kingdom|
|Study Director:||Damian J Mole, MB ChB||University of Edinburgh|